AT

ATUM CO., LTD.

Bioengineering solutions to accelerate life sciences research, from gene synthesis to cell lines.

355690 | KO

Overview

Corporate Details

ISIN(s):
KR7355690009
LEI:
Country:
South Korea
Address:
서울특별시 구로구 디지털로31길 38-9 에이스테크노타워1차 6층 603-2호, 구로구
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

ATUM is a biotechnology company that provides integrated solutions and tools for the life sciences industry. Specializing in advanced bioengineering, the company offers services designed to accelerate timelines from discovery and preclinical research to manufacturing and Investigational New Drug (IND) applications. Its core offerings include gene design and synthesis, vector and sequence optimization, protein engineering, and the development of high-producing cell lines. Founded as DNA2.0 in 2003, ATUM operates on a collaborative model, partnering with researchers to advance their projects in molecular biology and protein engineering.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.6 MB
2025-07-29 00:00
Capital/Financing Update
타인에대한채무보증결정
Korean 10.4 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.8 MB
2025-05-07 00:00
M&A Activity
합병등종료보고서(자산양수도)
Korean 15.1 KB
2025-05-02 00:00
Capital/Financing Update
단기차입금증가결정
Korean 9.4 KB
2025-04-29 00:00
Share Issue/Capital Change
주요사항보고서(전환사채권발행결정)
Korean 65.7 KB
2025-04-29 00:00
M&A Activity
[기재정정]주요사항보고서(타법인주식및출자증권양수결정)
Korean 57.6 KB
2025-04-29 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 70.0 KB
2025-04-29 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제4회차 CB)
Korean 6.0 KB
2025-04-02 00:00
M&A Activity
합병등종료보고서(자산양수도)
Korean 14.9 KB
2025-04-01 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.4 KB
2025-03-31 00:00
M&A Activity
[기재정정]주요사항보고서(타법인주식및출자증권양수결정)
Korean 49.2 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 23.9 KB
2025-03-28 00:00
Regulatory News Service
본점소재지변경
Korean 5.0 KB
2025-03-21 00:00
M&A Activity
[기재정정]주요사항보고서(타법인주식및출자증권양수결정)
Korean 49.3 KB

Automate Your Workflow. Get a real-time feed of all ATUM CO., LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ATUM CO., LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for ATUM CO., LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America
MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden
MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany
MYNZ
MANNKIND CORP Logo
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
United States of America
MNKD
MARAVAI LIFESCIENCES HOLDINGS, INC. Logo
Provides nucleic acid products and biologics safety testing for new therapies and vaccines.
United States of America
MRVI
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria
MARI
Marker Therapeutics, Inc. Logo
Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.
United States of America
MRKR
Matinas BioPharma Holdings, Inc. Logo
Developing oral drugs via a lipid nano-crystal platform for infections, oncology & inflammation.
United States of America
MTNB
Matricelf Ltd. Logo
Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.
Israel
MTLF
Maze Therapeutics, Inc. Logo
Develops genetic precision medicines for common diseases, with a focus on chronic kidney disease.
United States of America
MAZE

Talk to a Data Expert

Have a question? We'll get back to you promptly.